← Innate Pharma SA
| Annual Trend | FY 2015 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net income (loss) | — | ($48.4m) |
$3.0m
+106.30%
|
($20.8m)
-780.85%
|
($64.0m)
-208.22%
|
($52.8m)
+17.47%
|
($58.1m)
-10.02%
|
($7.6m)
+86.97%
|
($49.5m)
-553.51%
|
($49.2m)
+0.59%
|
— | |
| Net Income From Continuing Operations | — | — | — | — | — | — | ($58.1m) | ($49.2m) | ($49.5m) | ($7.6m) | ($7.6m) | |
| Other profit or loss items with no cash effect | — | — | $0 | $550k | ($254k) | ($1.2m) | $15k | $6k | $24k | ($2k) | — | |
| Profit or Loss | — | — | $3.0m | ($20.8m) | ($64.0m) | ($52.8m) | ($58.1m) | ($7.6m) | ($49.5m) | ($49.2m) | — | |
| Other Adjustments To Reconcile Profit Loss | — | — | — | $550k | ($254k) | ($1.2m) | $15k | $6k | $24k | ($2k) | — | |
| Depreciation and amortization, net | — | $4.4m | $7.4m | $16.5m | $56.8m | $4.6m | $45.4m | $5.1m | $2.0m | $1.4m | $5.1m | |
| Depreciation Amortization Depletion | — | — | — | — | — | — | $45.4m | $1.4m | $2.0m | $5.1m | $5.1m | |
| Depreciation And Amortization | — | — | — | — | — | — | $45.4m | $1.4m | $2.0m | $5.1m | $5.1m | |
| Adjustments For Share-Based Payments | — | — | $2.7m | $3.8m | $2.5m | $2.6m | $4.2m | $4.3m | $3.9m | $2.6m | — | |
| Share-based compensation expense | — | $9.8m | $2.7m | $3.8m | $2.5m | $2.6m | $4.2m | $4.3m | $3.9m | $2.6m | $4.3m | |
| Change in working capital | — | ($138.1m) | ($47.1m) | ($117.7m) | ($49.2m) | ($9.9m) | ($12.5m) | ($32.1m) | $39.2m | ($10.6m) | ($32.1m) | |
| Change in working capital, variance | — | — | — | — | — | — | — | — | $39.7m | ($10.3m) | ($32.1m) | |
| Change in working capital, adjusted | — | — | — | — | — | — | — | ($14.1m) | ($53.2m) | ($42.6m) | ($32.1m) | |
| Change In Receivables | — | — | — | — | — | $3.4m | ($4.2m) | — | — | — | ($4.2m) | |
| Changes In Account Receivables | — | — | — | — | — | $3.4m | ($4.2m) | — | — | — | ($4.2m) | |
| Trade receivables and others (excluding rebates related to capital expenditures) | — | $21.4m | ($117.6m) | $28.7m | $51.6m | $48.2m | $52.4m | $66.1m | $14.3m | $12.7m | — | |
| Trade receivables and others (excluding rebates related to capital expenditures), variance | — | — | — | $110.3m | ($22.9m) | $3.4m | ($4.2m) | ($13.7m) | $51.8m | $1.6m | — | |
| Trade payables and others (excluding payables related to capital expenditures) | — | ($24.6m) | $15.2m | ($36.0m) | ($29.5m) | ($28.6m) | ($20.9m) | ($17.0m) | ($16.0m) | ($15.0m) | — | |
| Trade payables and others (excluding payables related to capital expenditures), variance | — | — | — | $1.4m | ($6.5m) | ($946k) | ($7.7m) | ($3.9m) | ($1.0m) | ($965k) | — | |
| Change in accrued interests on financial assets | — | ($204k) | $152k | ($237k) | $372k | ($55k) | $118k | $0 | ($380k) | ($352k) | — | |
| Deferred revenue - current and non-current portion | — | ($134.9m) | $68.4m | ($89.1m) | ($44.0m) | ($37.9m) | ($14.5m) | ($10.5m) | ($3.4m) | ($2.8m) | — | |
| Disposal of other assets | — | — | $25k | ($10k) | $0 | $40k | $0 | $66k | $0 | $5k | — | |
| Acquisition of other assets | — | — | $25k | ($10k) | ($59k) | ($1k) | ($1k) | ($3k) | $0 | $0 | — | |
| Change In Other Current Liabilities | — | — | — | — | — | ($6.3m) | $22.8m | — | — | — | $22.8m | |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | — | $50k | $22k | ($1.3m) | $9k | $7k | $0 | $150k | $0 | $0 | — | |
| Capital Expenditure | — | — | — | — | — | — | ($1.1m) | ($140k) | ($391k) | ($2.4m) | ($2.4m) | |
| Net Other Investing Changes | — | — | — | — | — | — | ($1k) | $6k | $1k | $63k | $63k | |
| Net cash generated from / (used in) investing activities | — | ($29.5m) | $24.3m | ($62.1m) | ($13.4m) | ($917k) | $1.9m | $20.6m | $9.2m | $7.3m | — | |
| Proceeds From Borrowings Classified As Financing Activities | — | — | — | $13.9m | $1.4m | $28.7m | $0 | $0 | $0 | $0 | — | |
| Repayments Of Borrowings Classified As Financing Activities | — | — | $1.3m | $2.0m | $2.2m | $2.1m | $2.0m | $2.4m | $8.9m | $8.9m | — | |
| Repayment of borrowings | — | ($1.2m) | ($1.3m) | ($2.0m) | ($2.2m) | ($2.1m) | ($2.0m) | ($2.4m) | ($8.9m) | ($8.9m) | — | |
| Issuance Of Debt | — | — | — | — | — | $28.7m | $0 | $0 | — | — | $0 | |
| Long Term Debt Issuance | — | — | — | — | — | $28.7m | $0 | $0 | — | — | $0 | |
| Net Issuance Payments Of Debt | — | — | — | — | — | — | ($2.0m) | ($8.9m) | ($8.9m) | ($2.4m) | ($2.4m) | |
| Net Long Term Debt Issuance | — | — | — | — | — | — | ($2.0m) | ($8.9m) | ($8.9m) | ($2.4m) | ($2.4m) | |
| Long Term Debt Payments | — | — | — | — | — | — | ($2.0m) | ($8.9m) | ($8.9m) | ($2.4m) | ($2.4m) | |
| Repayment Of Debt | — | — | — | — | — | — | ($2.0m) | ($8.9m) | ($8.9m) | ($2.4m) | ($2.4m) | |
| Cash Dividends Paid | — | — | — | — | — | $0 | $0 | $0 | — | — | $0 | |
| Net cash generated from / (used in) financing activities | — | $915k |
$61.2m
+6590.93%
|
$77.8m
+27.02%
|
($1.2m)
-101.51%
|
$26.8m
+2378.50%
|
($1.8m)
-106.82%
|
($2.0m)
-7.55%
|
($6.0m)
-205.60%
|
$6.1m
+201.03%
|
— | |
| Net increase / (decrease) in cash and cash equivalents | — | ($76.5m) | $52.9m | $50.6m | ($66.1m) | ($33.0m) | ($19.5m) | ($13.6m) | ($4.2m) | ($38.3m) | — | |
| Beginning Cash Position | — | — | — | — | — | — | $103.8m | $66.4m | $70.6m | $84.2m | $84.2m | |
| Cash and cash equivalents at the beginning of the year | — | $99.4m | $152.3m | $202.9m | $136.8m | $103.8m | $84.2m | $70.6m | $66.4m | $28.1m | — | |
| Effect of the exchange rate changes | — | $66k | ($26k) | $5k | $219k | ($483k) | ($428k) | $274k | ($505k) | $1.1m | — | |
| Effect Of Exchange Rate Changes | — | — | — | — | — | — | ($428k) | $1.1m | ($505k) | $274k | $274k | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Additional Financial Items | ||||||||||||
| Adjustments For Finance Costs | — | — | — | — | $341k | $312k | $0 | $0 | — | — | — | |
| Adjustments For Finance Income | — | — | — | — | $962k | $367k | $0 | $991k | $0 | $0 | — | |
| Adjustments For Unrealised Foreign Exchange Losses Gains | — | — | ($1.3m) | ($280k) | $1.3m | ($1.1m) | ($912k) | $544k | ($885k) | $1.4m | — | |
| General And Administrative Expense | — | — | $18.1m | — | — | — | — | — | — | $19.4m | — | |
| Increase Decrease In Working Capital | — | — | $47.1m | ($40.2m) | $49.2m | $9.9m | $12.5m | $32.1m | ($39.2m) | $10.6m | ($32.1m) | |
| Interest Received Classified As Operating Activities | — | — | — | — | — | — | — | — | $1.9m | $1.8m | — | |
| Proceeds From Issuing Shares | — | — | — | — | $48k | $499k | $198k | $395k | $2.9m | $15.0m | — | |
| Purchase Of Intangible Assets Classified As Investing Activities | — | — | $556k | $64.1m | $10.4m | $401k | $587k | $2.0m | $0 | $0 | — | |
| Employee benefits costs | — | $381k | $477k | $685k | $216k | $437k | $365k | $285k | $324k | ($807k) | — | |
| Change in provisions | — | $877k | ($322k) | ($484k) | $604k | $4k | $839k | ($966k) | ($293k) | $3.3m | — | |
| Change in fair value of financial assets | — | ($26k) | $3.8m | ($4.1m) | $577k | ($987k) | $1.4m | ($1.6m) | ($1.3m) | ($451k) | — | |
| Foreign exchange (gains) losses on financial assets | — | $3.4m | ($1.3m) | ($280k) | $1.3m | ($1.1m) | ($912k) | $544k | ($885k) | $1.4m | — | |
| Gains (losses) on assets and other financial assets | — | — | ($1.4m) | ($1.3m) | ($962k) | ($367k) | $0 | ($991k) | $0 | $0 | — | |
| Acquisition of intangible assets | ($6.3m) | ($3.1m) | ($556k) | ($64.1m) | ($10.4m) | ($401k) | ($587k) | ($2.0m) | $0 | $0 | — | |
| Disposal of non-current financial instruments | — | $11.9m | $21.5m | $2.0m | $0 | $0 | $3.0m | $22.8m | $0 | $0 | — | |
| Interest received on financial assets | — | $1.4m | $1.4m | $1.3m | $962k | $367k | $0 | $0 | $0 | $388k | — | |
| Proceeds from the exercise / subscription of equity instruments | — | $491k | $111k | $44k | $48k | $499k | $198k | $395k | $2.9m | $15.0m | — | |
| Collaboration liabilities - current and non-current portion | — | — | $13.1m | ($21.3m) | ($46.7m) | ($40.4m) | ($63.2m) | ($52.7m) | ($48.6m) | ($38.2m) | — | |
| Collaboration liabilities - current and non-current portion, variance | — | — | — | ($10.4m) | $25.4m | ($6.3m) | $22.8m | ($10.5m) | ($4.1m) | ($10.3m) | — | |
| 5% retained - Tax credit refund | — | — | — | — | — | — | — | $0 | $490k | $868k | — | |
| 5% retained - Tax credit refund, variance | — | — | — | — | — | — | — | — | ($490k) | ($378k) | — | |
| Cash Flow From Continuing Financing Activities | — | — | — | — | — | — | ($1.8m) | $6.1m | ($6.0m) | ($2.0m) | ($2.0m) | |
| Cash Flow From Continuing Investing Activities | — | — | — | — | — | — | $1.9m | $7.3m | $9.2m | $20.6m | $20.6m | |
| Change In Account Payable | — | — | — | — | — | ($946k) | ($7.7m) | — | — | — | ($7.7m) | |
| Change In Other Working Capital | — | — | — | — | — | ($6.1m) | ($23.4m) | — | — | — | ($23.4m) | |
| Change In Payable | — | — | — | — | — | ($946k) | ($7.7m) | — | — | — | ($7.7m) | |
| Changes In Cash | — | — | — | — | — | — | ($19.1m) | ($39.4m) | ($3.7m) | ($13.9m) | ($13.9m) | |
| End Cash Position | — | — | — | — | — | — | $84.2m | $28.1m | $66.4m | $70.6m | $70.6m | |
| Financing Cash Flow | — | — | — | — | — | — | ($1.8m) |
$6.1m
+432.06%
|
($6.0m)
-198.98%
|
($2.0m)
+67.28%
|
($2.0m)
0.00%
|
|
| Free Cash Flow | — | — | — | — | — | — | ($20.3m) | ($52.9m) | ($7.3m) | ($34.9m) | ($34.9m) | |
| Gain Loss On Investment Securities | — | — | — | — | — | ($1.1m) | ($912k) | — | — | — | $1.4m | |
| Gain Loss On Sale Of PPE | — | — | — | — | — | — | $0 | $23k | $20k | $470k | $470k | |
| Interest Received CFI | — | — | — | — | — | — | $0 | $388k | $0 | $0 | $0 | |
| Investing Cash Flow | — | — | — | — | — | — | $1.9m | $7.3m | $9.2m | $20.6m | $20.6m | |
| Net Foreign Currency Exchange Gain Loss | — | — | — | — | — | — | ($912k) | $1.4m | ($885k) | $544k | $544k | |
| Net Intangibles Purchase And Sale | — | — | — | — | — | — | ($587k) | $0 | $0 | ($2.0m) | ($2.0m) | |
| Net PPE Purchase And Sale | — | — | — | — | — | — | ($535k) | ($140k) | ($391k) | ($201k) | ($201k) | |
| Operating Gains Losses | — | — | — | — | — | — | ($547k) | $578k | ($541k) | $308k | $308k | |
| Other Non Cash Items | — | — | — | — | — | — | $133k | ($354k) | ($356k) | $6k | — | |
| Pension And Employee Benefit Expense | — | — | — | — | — | — | $365k | ($807k) | $324k | $285k | $285k | |
| Proceeds From Stock Option Exercised | — | — | — | — | — | — | $198k | $15.0m | $2.9m | $395k | $395k | |
| Provisionand Write Offof Assets | — | — | — | — | — | — | $839k | $3.3m | ($293k) | ($966k) | ($966k) | |
| Purchase Of Intangibles | — | — | — | — | — | — | ($587k) | $0 | $0 | ($2.0m) | ($2.0m) | |
| Purchase Of PPE | — | — | — | $1.3m | $907k | $929k | ($535k) | ($140k) | ($391k) | ($351k) | ($2.4m) | |
| Sale Of PPE | — | — | — | — | — | — | $0 | $0 | $0 | $150k | $150k | |
| Stock Based Compensation | — | — | — | — | — | — | $4.2m | $2.6m | $3.9m | $4.3m | $4.3m | |
| Unrealized Gain Loss On Investment Securities | — | — | — | — | — | — | $1.4m | ($451k) | ($1.3m) | ($1.6m) | ($1.6m) | |
| Net Investment Purchase And Sale | — | — | — | — | — | — | $3.0m | $7.0m | $9.6m | $22.8m | $22.8m | |
| Purchase Of Investment | — | — | — | — | — | $0 | $0 | $0 | — | — | $0 | |
| Sale Of Investment | — | — | — | — | — | — | $3.0m | $7.0m | $9.6m | $22.8m | $22.8m | |
| Change In Cash Supplemental As Reported | — | — | — | — | — | — | ($19.5m) | ($38.3m) | ($4.2m) | ($13.6m) | — | |
| Interest Paid Classified As Financing Activities | — | ($113k) | $102k | $204k | $341k | $312k | $0 | $0 | $9.6m | $7.0m | — | |
| Interest Paid Classified As Operating Activities | — | ($113k) | ($102k) | ($204k) | ($341k) | ($312k) | $0 | $0 | $1.3m | $400k | — | |
| Income Taxes Paid Refund Classified As Operating Activities | — | — | — | — | — | — | — | — | ($8.6m) | ($6.5m) | — |